Jun 03, 2020
Zeulide Depot(TM) is now Covered by the Ontario Drug Benefit (ODB) Program for Patients Living with Prostate Cancer
May 29, 2020
XTANDI® (enzalutamide) Approved by Japan MHLW for the Treatment of Prostate Cancer with Distant Metastasis
May 13, 2020
ERLEADA® (apalutamide) Significantly Improved Overall Survival in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Nov 25, 2019
Astellas Announces the Approval of XTANDI® (enzalutamide) by the China National Medical Products Administration (NMPA)
Sep 17, 2019
U.S. FDA Approves Supplemental New Drug Application (sNDA) for ERLEADA® (apalutamide) for the Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
May 31, 2019
ERLEADA® (apalutamide) Significantly Improved Overall Survival (OS) and Radiographic Progression-Free Survival (rPFS) in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
May 05, 2019
Studies Bring Focus To Impact Of Urologic Disease On Mental, Emotional Health
Apr 29, 2019
U.S. FDA accepts New Drug Application and grants Priority Review for darolutamide
Feb 27, 2019
Bayer completes rolling submission of New Drug Application to U.S. Food and Drug Administration for investigational drug darolutamide for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC)
Feb 14, 2019
Bayer's investigational drug darolutamide plus androgen deprivation therapy (ADT) significantly extends metastasis-free survival compared to placebo plus ADT in non-metastatic castration-resistant prostate cancer
Nov 01, 2018
Combined therapy including pelvic lymph node radiation provides significant benefit for prostate cancer patients
Oct 31, 2018
Men with low- and intermediate-risk prostate cancer can safely benefit from fewer, higher-dose radiation treatments
Oct 24, 2018
Phase III Trial of Darolutamide in Patients with Non-metastatic Castration-resistant Prostate Cancer Meets Primary Endpoint
Sep 24, 2018
Astellas Receives Positive CHMP Opinion for XTANDI® (enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer
Sep 11, 2018
Health-Related Quality of Life Maintained with Addition of ERLEADA® to Androgen Deprivation Therapy for Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Jul 13, 2018
U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
Jul 04, 2018
Health Canada Approves ERLEADA(TM)* (apalutamide tablets), the First Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer
May 18, 2018
ERLEADA(TM) Significantly Reduced Risk of Prostate Specific Antigen (PSA) Progression in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Feb 15, 2018
Health Canada Approves New Indication for ZYTIGA®* (abiraterone acetate), Broadening its Use for Treatment of Newly Diagnosed Metastatic Prostate Cancer
Feb 14, 2018
ERLEADA(TM) (apalutamide), a Next-Generation Androgen Receptor Inhibitor, Granted U.S. FDA Approval for the Treatment of Patients with Non-Metastatic Castration-Resistant Prostate Cancer